UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Utility of SPR technology in biotherapeutic development: Qualification for intended use

Analytical biochemistry, 2022-10, Vol.654, p.114804-114804, Article 114804

2022

Volltextzugriff (PDF)

Galectins and Immune Responses-Just How Do They Do Those Things They Do?

Annual review of immunology, 2016-05, Vol.34 (1), p.243-264

2016

Volltextzugriff (PDF)

Effects of Adding Linagliptin to Basal Insulin Regimen for Inadequately Controlled Type 2 Diabetes

Diabetes care, 2013-12, Vol.36 (12), p.3875-3881

2013

Volltextzugriff (PDF)

Effects of Adding Linagliptin to Basal Insulin Regimen for Inadequately Controlled Type 2 Diabetes: A ≥52-week randomized, double-blind study

Diabetes care, 2013-12, Vol.36 (12), p.3875-3881

2013

Volltextzugriff (PDF)

Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA‐T2D trial

Diabetes, obesity & metabolism, 2017-11, Vol.19 (11), p.1610-1619

2017

Volltextzugriff (PDF)

Functional similarity of ABP 959 and eculizumab in simulated serum models of aHUS and NMOSD

Annals of hematology, 2023-12, Vol.102 (12), p.3299-3309

2023

Volltextzugriff (PDF)

Galectin-1 Regulates Tissue Exit of Specific Dendritic Cell Populations

The Journal of biological chemistry, 2015-09, Vol.290 (37), p.22662-22677

2015

Volltextzugriff (PDF)

Kardiovaskuläre Studien-Endpunkte bei Typ-2-Diabetes und die Sulfonylharnstoff-Kontroverse

Deutsche medizinische Wochenschrift, 2015-05, Vol.140 (11), p.831-834

2015

Volltextzugriff (PDF)

A randomised, active- and placebo-controlled, three-period crossover trial to investigate short-term effects of the dipeptidyl peptidase-4 inhibitor linagliptin on macro- and microvascular endothelial function in type 2 diabetes

Cardiovascular diabetology, 2017-01, Vol.16 (1), p.13-13, Article 13

2017

Volltextzugriff (PDF)

Safety and efficacy of linagliptin in patients with type 2 diabetes mellitus and coronary artery disease: Analysis of pooled events from 19 clinical trials

Journal of diabetes and its complications, 2016-09, Vol.30 (7), p.1378-1384

2016

Volltextzugriff (PDF)

Efficacy and Safety of Linagliptin Co-Administered with Low-Dose Metformin Once Daily Versus High-Dose Metformin Twice Daily in Treatment-Naïve Patients with Type 2 Diabetes: a Double-Blind Randomized Trial

Advances in therapy, 2015-03, Vol.32 (3), p.201-215

2015

Volltextzugriff (PDF)

The Road Less Traveled: Regulation of Leukocyte Migration Across Vascular and Lymphatic Endothelium by Galectins

Journal of clinical immunology, 2011-02, Vol.31 (1), p.2-9

2011

Volltextzugriff (PDF)

Assessing the roles of galectins in regulating dendritic cell migration through extracellular matrix and across lymphatic endothelial cells

Methods in molecular biology (Clifton, N.J.), 2015-01, Vol.1207, p.215

2015

Volltextzugriff (PDF)

Linagliptin reduces the diabetic nephropathy score, DN_Score, in patients with T2DM and microalbuminuria: A predefined substudy from the MARLINA-T2D™ trial

Diabetes research and clinical practice, 2016-10, Vol.120, p.S129-S129

2016

Volltextzugriff (PDF)

PD-120 - Linagliptin reduces the diabetic nephropathy score, DN_Score, in patients with T2DM and microalbuminuria: A predefined substudy from the MARLINA-T2D™ trial

Diabetes research and clinical practice, 2016-10, Vol.120, p.S129-S129

2016

Volltextzugriff (PDF)

Apoptosis of a T cell population following cross‐linking of CD8

The FASEB journal, 2008-04, Vol.22 (S2), p.359-359

2008

Volltextzugriff (PDF)

A RANDOMIZED, ACTIVE- AND PLACEBO-CONTROLLED, THREE-PERIOD CROSSOVER TRIAL TO INVESTIGATE SHORT-TERM EFFECTS OF THE DIPEPTIDYL PEPTIDASE-4 INHIBITOR LINAGLIPTIN ON ENDOTHELIAL FUNCTION IN TYPE 2 DIABETES

Journal of the American College of Cardiology, 2015-03, Vol.65 (10), p.A2080-A2080

2015

Volltextzugriff (PDF)

Effects of Adding Linagliptin to Basal Insulin Regimen for Inadequately Controlled Type 2 Diabetes: A [Greater-Than Or Equal To]52-week randomized, double-blind study

Diabetes care, 2013-12, Vol.36 (12), p.3881

2013

Volltextzugriff (PDF)

Linagliptin plus metformin in patients with newly diagnosed type 2 diabetes and marked hyperglycemia

Postgraduate medicine, 2016-11, Vol.128 (8), p.747-754

2016

Volltextzugriff (PDF)

new function for LAT and CD8 during CD8-mediated apoptosis that is independent of TCR signal transduction

European journal of immunology, 2009-06, Vol.39 (6), p.1619-1631

2009

Volltextzugriff (PDF)

A New Function for LAT and CD8 During CD8-Mediated Apoptosis that is Independent of T Cell Receptor Signal Transduction

European journal of immunology, 2009-06, Vol.39 (6), p.1619-1631

2009

Volltextzugriff (PDF)

Letter to the editor regarding: "Pharmacokinetics of teneligliptin in subjects with renal impairment." Halabi et al., Clinical Pharmacology in Drug Development 2013;2:246-254

Clinical pharmacology in drug development, 2014-09, Vol.3 (5), p.417-418

2014

Volltextzugriff (PDF)

Efficacy and Safety of Linagliptin as Add-on Therapy to Basal Insulin in Patients With Type 2 Diabetes

Canadian journal of diabetes, 2012-10, Vol.36 (5), p.S39-S39

2012

Volltextzugriff (PDF)

The opposing effects of CD8 and CD8+TCR/CD3 engagement on thymocyte and peripheral T cell apoptosis: A role for CD8 sialylation and membrane rigidity

Thiemann, Sandra

2009

Volltextzugriff (PDF)

International Conference in Integrative Medicine ICIM – 2020

Integrative Medicine Case Reports, 2021, Vol.2 (1), p.4

2021

Volltextzugriff (PDF)

1 – 25 von 46

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(39)
Mit Volltextzugriff
(37)

Publikationsform

Sprache

Englisch
(42)
Deutsch
(4)

Erscheinungsjahr

n.n

Thema

Science & Technology
(27)
Life Sciences & Biomedicine
(22)
Humans
(18)
Middle Aged
(12)
Female
(11)
Male
(11)
Aged
(10)
Adult
(8)
Diabetes Mellitus, Type 2 - Drug Therapy
(7)
Endocrinology & Metabolism
(7)
Linagliptin
(7)
Biological And Medical Sciences
(6)
Drug Therapy, Combination
(6)
Medical Sciences
(6)
Treatment Outcome
(6)
Animals
(5)
Biochemistry & Molecular Biology
(5)
Double-Blind Method
(5)
Follow-Up Studies
(5)
Linagliptin - Therapeutic Use
(5)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Utility of SPR technology in biotherapeutic development: Qualification for intended use

Galectins and Immune Responses-Just How Do They Do Those Things They Do?

Effects of Adding Linagliptin to Basal Insulin Regimen for Inadequately Controlled Type 2 Diabetes

Effects of Adding Linagliptin to Basal Insulin Regimen for Inadequately Controlled Type 2 Diabetes: A ≥52-week randomized, double-blind study

Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA‐T2D trial

Functional similarity of ABP 959 and eculizumab in simulated serum models of aHUS and NMOSD

Galectin-1 Regulates Tissue Exit of Specific Dendritic Cell Populations

Kardiovaskuläre Studien-Endpunkte bei Typ-2-Diabetes und die Sulfonylharnstoff-Kontroverse

A randomised, active- and placebo-controlled, three-period crossover trial to investigate short-term effects of the dipeptidyl peptidase-4 inhibitor linagliptin on macro- and microvascular endothelial function in type 2 diabetes

Safety and efficacy of linagliptin in patients with type 2 diabetes mellitus and coronary artery disease: Analysis of pooled events from 19 clinical trials

Efficacy and Safety of Linagliptin Co-Administered with Low-Dose Metformin Once Daily Versus High-Dose Metformin Twice Daily in Treatment-Naïve Patients with Type 2 Diabetes: a Double-Blind Randomized Trial

The Road Less Traveled: Regulation of Leukocyte Migration Across Vascular and Lymphatic Endothelium by Galectins

Assessing the roles of galectins in regulating dendritic cell migration through extracellular matrix and across lymphatic endothelial cells

Linagliptin reduces the diabetic nephropathy score, DN_Score, in patients with T2DM and microalbuminuria: A predefined substudy from the MARLINA-T2D™ trial

PD-120 - Linagliptin reduces the diabetic nephropathy score, DN_Score, in patients with T2DM and microalbuminuria: A predefined substudy from the MARLINA-T2D™ trial

Apoptosis of a T cell population following cross‐linking of CD8

A RANDOMIZED, ACTIVE- AND PLACEBO-CONTROLLED, THREE-PERIOD CROSSOVER TRIAL TO INVESTIGATE SHORT-TERM EFFECTS OF THE DIPEPTIDYL PEPTIDASE-4 INHIBITOR LINAGLIPTIN ON ENDOTHELIAL FUNCTION IN TYPE 2 DIABETES

Effects of Adding Linagliptin to Basal Insulin Regimen for Inadequately Controlled Type 2 Diabetes: A [Greater-Than Or Equal To]52-week randomized, double-blind study

Linagliptin plus metformin in patients with newly diagnosed type 2 diabetes and marked hyperglycemia

new function for LAT and CD8 during CD8-mediated apoptosis that is independent of TCR signal transduction

A New Function for LAT and CD8 During CD8-Mediated Apoptosis that is Independent of T Cell Receptor Signal Transduction

Letter to the editor regarding: "Pharmacokinetics of teneligliptin in subjects with renal impairment." Halabi et al., Clinical Pharmacology in Drug Development 2013;2:246-254

Efficacy and Safety of Linagliptin as Add-on Therapy to Basal Insulin in Patients With Type 2 Diabetes

The opposing effects of CD8 and CD8+TCR/CD3 engagement on thymocyte and peripheral T cell apoptosis: A role for CD8 sialylation and membrane rigidity

International Conference in Integrative Medicine ICIM – 2020

Suchergebnisse filtern